Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009

CYTOKINETICS, INC. (CYTK)

8
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

React to this article
Latest news on CYTOKINETICS, INC.
12/05 CYTOKINETICS : Other Events (form 8-K)
12/05 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv & Effects on Respi..
12/05 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv and Effects on Res..
12/01 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv at the 25th Intern..
12/01 CYTOKINETICS : Assigned Patent
11/26 CYTOKINETICS : to Participate in the 26th Annual Piper Jaffray Healthcare Confer..
11/10 CYTOKINETICS' : President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse ..
11/06 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
11/03 CYTOKINETICS : Reports Third Quarter 2014 Financial Results
11/03 CYTOKINETICS : Assigned Patent
Advertisement
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF